



MEDIA STATEMENT

bioMérieux supporting the launch of the AMR Industry Alliance

Marcy l'Etoile, France, May 2017 - bioMérieux, a world leader in the field of *in vitro* diagnostics, is pleased to support the launch of the **AMR Industry Alliance**, a new alliance to drive and measure industry progress to curb antimicrobial resistance.

bioMérieux Chief Medical Officer, Mark Miller, MD. will serve on the Alliance Board, representing the diagnostic industry along with Andrew Fish, Executive Director, AdvaMedDx.

bioMérieux has been a pioneer in the diagnosis of infectious diseases and is a strong advocate of the fight against resistance. Most recently, bioMérieux signed the Industry Declaration on AMR at World Economic Forum in Davos.

“Every one of us is concerned by antimicrobial resistance, a global public health challenge. Diagnostic tools are key to maintain antibiotic effectiveness for future generations,” explained Mark Miller, bioMérieux Corporate VP, Chief Medical Officer.

To learn more about the AMR Industry Alliance, read their latest press release: <http://bit.ly/2qk2rlz>

About bioMérieux

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 50 over years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2016, revenues reached €2,103 million with 90% of international sales.

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market (Symbol: BIM – ISIN: FR0010096479).
Corporate website: www.biomerieux.com

Media Contact

bioMérieux
Aurore Sergeant
Tel.: + 33 (0)4 78 87 20 53
media@biomerieux.com